A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2020-03, Vol.156 (3), p.689-694
Hauptverfasser: Salminen, Liina, Nadeem, Nimrah, Jain, Shruti, Grènman, Seija, Carpén, Olli, Hietanen, Sakari, Oksa, Sinikka, Lamminmäki, Urpo, Pettersson, Kim, Gidwani, Kamlesh, Huhtinen, Kaisa, Hynninen, Johanna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 694
container_issue 3
container_start_page 689
container_title Gynecologic oncology
container_volume 156
creator Salminen, Liina
Nadeem, Nimrah
Jain, Shruti
Grènman, Seija
Carpén, Olli
Hietanen, Sakari
Oksa, Sinikka
Lamminmäki, Urpo
Pettersson, Kim
Gidwani, Kamlesh
Huhtinen, Kaisa
Hynninen, Johanna
description Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CA125-STn and CA125-MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. •CA125-STn is a more sensitive indicator of tumor load than conventional CA125.•The nadir value of CA125-STn is a predictor of progression free survival.•The CA125-STn assay detects relapse more precisely than the conventional CA125 assay.
doi_str_mv 10.1016/j.ygyno.2019.12.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2331634149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825819318463</els_id><sourcerecordid>2331634149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-2e57ad86f3f3732f0e1700857e129958456243c82a9477f79de4ef615674bde93</originalsourceid><addsrcrecordid>eNp9kDuP1DAURi0EYoeFX4CEXNIk-JnYBcVotDyklWigtrzxdcajxB7sZFH-PR5moaS5tznffRyE3lLSUkK7D6d2G7eYWkaobilrCZPP0I4SLZtOSf0c7QjRpFFMqhv0qpQTIYQTyl6iG06V0pKpHUp7PKU4hmV1IdoJ21q2EgpOHh_2lEk8TtuQfMpzwSHi5Qh4TjEsKYc4Vtxhn6Yp_cLr-ZI5hvGIx2wd4AI5rXXQo83BRjzYOEB-jV54OxV489Rv0Y9Pd98PX5r7b5-_Hvb3zSCIWBoGsrdOdZ573nPmCdCeECV7oExrqYTsmOCDYlaLvve9diDAd1R2vXhwoPkten-de87p5wplMXMoA0yTjVCvMoxz2nFBxQXlV3TIqZQM3pxzmG3eDCXmYtqczB_T5mLaUGaq6Zp697RgfZjB_cv8VVuBj1cA6puPAbIpQ4DqwIUMw2JcCv9d8BszE5Aa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331634149</pqid></control><display><type>article</type><title>A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Salminen, Liina ; Nadeem, Nimrah ; Jain, Shruti ; Grènman, Seija ; Carpén, Olli ; Hietanen, Sakari ; Oksa, Sinikka ; Lamminmäki, Urpo ; Pettersson, Kim ; Gidwani, Kamlesh ; Huhtinen, Kaisa ; Hynninen, Johanna</creator><creatorcontrib>Salminen, Liina ; Nadeem, Nimrah ; Jain, Shruti ; Grènman, Seija ; Carpén, Olli ; Hietanen, Sakari ; Oksa, Sinikka ; Lamminmäki, Urpo ; Pettersson, Kim ; Gidwani, Kamlesh ; Huhtinen, Kaisa ; Hynninen, Johanna</creatorcontrib><description>Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CA125-STn and CA125-MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. •CA125-STn is a more sensitive indicator of tumor load than conventional CA125.•The nadir value of CA125-STn is a predictor of progression free survival.•The CA125-STn assay detects relapse more precisely than the conventional CA125 assay.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2019.12.025</identifier><identifier>PMID: 31889528</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>CA125 ; Glycoform ; High grade serous ovarian carcinoma ; Ovarian cancer</subject><ispartof>Gynecologic oncology, 2020-03, Vol.156 (3), p.689-694</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-2e57ad86f3f3732f0e1700857e129958456243c82a9477f79de4ef615674bde93</citedby><cites>FETCH-LOGICAL-c404t-2e57ad86f3f3732f0e1700857e129958456243c82a9477f79de4ef615674bde93</cites><orcidid>0000-0003-4734-4743 ; 0000-0001-9685-5246 ; 0000-0001-6177-4139 ; 0000-0002-0854-7225</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2019.12.025$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31889528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salminen, Liina</creatorcontrib><creatorcontrib>Nadeem, Nimrah</creatorcontrib><creatorcontrib>Jain, Shruti</creatorcontrib><creatorcontrib>Grènman, Seija</creatorcontrib><creatorcontrib>Carpén, Olli</creatorcontrib><creatorcontrib>Hietanen, Sakari</creatorcontrib><creatorcontrib>Oksa, Sinikka</creatorcontrib><creatorcontrib>Lamminmäki, Urpo</creatorcontrib><creatorcontrib>Pettersson, Kim</creatorcontrib><creatorcontrib>Gidwani, Kamlesh</creatorcontrib><creatorcontrib>Huhtinen, Kaisa</creatorcontrib><creatorcontrib>Hynninen, Johanna</creatorcontrib><title>A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CA125-STn and CA125-MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. •CA125-STn is a more sensitive indicator of tumor load than conventional CA125.•The nadir value of CA125-STn is a predictor of progression free survival.•The CA125-STn assay detects relapse more precisely than the conventional CA125 assay.</description><subject>CA125</subject><subject>Glycoform</subject><subject>High grade serous ovarian carcinoma</subject><subject>Ovarian cancer</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kDuP1DAURi0EYoeFX4CEXNIk-JnYBcVotDyklWigtrzxdcajxB7sZFH-PR5moaS5tznffRyE3lLSUkK7D6d2G7eYWkaobilrCZPP0I4SLZtOSf0c7QjRpFFMqhv0qpQTIYQTyl6iG06V0pKpHUp7PKU4hmV1IdoJ21q2EgpOHh_2lEk8TtuQfMpzwSHi5Qh4TjEsKYc4Vtxhn6Yp_cLr-ZI5hvGIx2wd4AI5rXXQo83BRjzYOEB-jV54OxV489Rv0Y9Pd98PX5r7b5-_Hvb3zSCIWBoGsrdOdZ573nPmCdCeECV7oExrqYTsmOCDYlaLvve9diDAd1R2vXhwoPkten-de87p5wplMXMoA0yTjVCvMoxz2nFBxQXlV3TIqZQM3pxzmG3eDCXmYtqczB_T5mLaUGaq6Zp697RgfZjB_cv8VVuBj1cA6puPAbIpQ4DqwIUMw2JcCv9d8BszE5Aa</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Salminen, Liina</creator><creator>Nadeem, Nimrah</creator><creator>Jain, Shruti</creator><creator>Grènman, Seija</creator><creator>Carpén, Olli</creator><creator>Hietanen, Sakari</creator><creator>Oksa, Sinikka</creator><creator>Lamminmäki, Urpo</creator><creator>Pettersson, Kim</creator><creator>Gidwani, Kamlesh</creator><creator>Huhtinen, Kaisa</creator><creator>Hynninen, Johanna</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4734-4743</orcidid><orcidid>https://orcid.org/0000-0001-9685-5246</orcidid><orcidid>https://orcid.org/0000-0001-6177-4139</orcidid><orcidid>https://orcid.org/0000-0002-0854-7225</orcidid></search><sort><creationdate>202003</creationdate><title>A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer</title><author>Salminen, Liina ; Nadeem, Nimrah ; Jain, Shruti ; Grènman, Seija ; Carpén, Olli ; Hietanen, Sakari ; Oksa, Sinikka ; Lamminmäki, Urpo ; Pettersson, Kim ; Gidwani, Kamlesh ; Huhtinen, Kaisa ; Hynninen, Johanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-2e57ad86f3f3732f0e1700857e129958456243c82a9477f79de4ef615674bde93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>CA125</topic><topic>Glycoform</topic><topic>High grade serous ovarian carcinoma</topic><topic>Ovarian cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salminen, Liina</creatorcontrib><creatorcontrib>Nadeem, Nimrah</creatorcontrib><creatorcontrib>Jain, Shruti</creatorcontrib><creatorcontrib>Grènman, Seija</creatorcontrib><creatorcontrib>Carpén, Olli</creatorcontrib><creatorcontrib>Hietanen, Sakari</creatorcontrib><creatorcontrib>Oksa, Sinikka</creatorcontrib><creatorcontrib>Lamminmäki, Urpo</creatorcontrib><creatorcontrib>Pettersson, Kim</creatorcontrib><creatorcontrib>Gidwani, Kamlesh</creatorcontrib><creatorcontrib>Huhtinen, Kaisa</creatorcontrib><creatorcontrib>Hynninen, Johanna</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salminen, Liina</au><au>Nadeem, Nimrah</au><au>Jain, Shruti</au><au>Grènman, Seija</au><au>Carpén, Olli</au><au>Hietanen, Sakari</au><au>Oksa, Sinikka</au><au>Lamminmäki, Urpo</au><au>Pettersson, Kim</au><au>Gidwani, Kamlesh</au><au>Huhtinen, Kaisa</au><au>Hynninen, Johanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2020-03</date><risdate>2020</risdate><volume>156</volume><issue>3</issue><spage>689</spage><epage>694</epage><pages>689-694</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CA125-STn and CA125-MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. •CA125-STn is a more sensitive indicator of tumor load than conventional CA125.•The nadir value of CA125-STn is a predictor of progression free survival.•The CA125-STn assay detects relapse more precisely than the conventional CA125 assay.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31889528</pmid><doi>10.1016/j.ygyno.2019.12.025</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4734-4743</orcidid><orcidid>https://orcid.org/0000-0001-9685-5246</orcidid><orcidid>https://orcid.org/0000-0001-6177-4139</orcidid><orcidid>https://orcid.org/0000-0002-0854-7225</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2020-03, Vol.156 (3), p.689-694
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_2331634149
source ScienceDirect Journals (5 years ago - present)
subjects CA125
Glycoform
High grade serous ovarian carcinoma
Ovarian cancer
title A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A12%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20longitudinal%20analysis%20of%20CA125%20glycoforms%20in%20the%20monitoring%20and%20follow%20up%20of%20high%20grade%20serous%20ovarian%20cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Salminen,%20Liina&rft.date=2020-03&rft.volume=156&rft.issue=3&rft.spage=689&rft.epage=694&rft.pages=689-694&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2019.12.025&rft_dat=%3Cproquest_cross%3E2331634149%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331634149&rft_id=info:pmid/31889528&rft_els_id=S0090825819318463&rfr_iscdi=true